16 May
2024
VALIRX PLC
("ValiRx" or the
"Company")
Further re Final
Results
ValiRx plc (the "Company") (AIM:
VAL), a life sciences company focusing on early-stage cancer
therapeutics and women's health, announces
that, following the publication of its audited results for the year
ended 31 December 2023 on 15 May 2024 and shareholder feedback and
communication, a clarification as to its cash position and recent
fundraising activities.
As stated in the announcement of 15 May 2024,
the cash balance of the Company as at 31 December 2023 was
£174,684. Subsequent to the financial year end and as set out in
the same announcement, the Company raised
approximately £1.8m, before expenses, through the issue of new
ordinary shares in January 2024. As at 15 May 2024, the Company's
cash position was approximately £1.1m.
The information contained within this
announcement is deemed by the Company to constitute inside
information as stipulated under the Market Abuse Regulations (EU)
No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of
the Company take responsibility for this announcement
For more information, please
contact:
|
ValiRx
plc
Dr Suzanne Dilly, CEO
|
Tel: +44 (0)
115 784 0026
www.valirx.com
Suzanne.Dilly@valirx.com
|
|
V Formation
(Public Relations)
Lucy Wharton - Senior PR Executive
Sue Carr - Director
|
+44 (0) 115
787 0206
www.vformation.biz
lucy@vformation.biz
sue@vformation.biz
|
|
Cairn
Financial Advisers LLP (Nominated Adviser)
Liam Murray/Jo Turner/Ludovico
Lazzaretti
|
Tel: +44 (0)
20 7213 0880
|
|
Shard Capital
Partners LLP (Sole Broker)
Damon Heath
|
Tel: +44 (0)
20 7186 9000
|
Notes for
Editors
About
ValiRx
ValiRx is a life science company focused on
early-stage cancer therapeutics and women's health, accelerating
the translation of innovative science into impactful medicines to
improve patient lives.
ValiRx provides the scientific, financial, and
commercial framework for enabling rapid translation of innovative
science into clinical development.
Using its extensive and proven experience in
research and drug development, the team at ValiRx selects and
incubates promising novel drug candidates and guides them through
an optimised process of development, from pre-clinical studies to
clinic and investor-ready assets.
ValiRx connects diverse disciplines across
scientific, technical, and commercial domains, with the aim of
achieving a more streamlined, less costly, drug development
process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for
science to advance.
Lead candidates from ValiRx's portfolio are
out-licensed or partnered with investors through ValiRx subsidiary
companies for further clinical development and
commercialisation.
ValiRx listed on the AIM Market of the London
Stock Exchange in October 2006 and trades under the ticker symbol:
VAL.
For further information, visit:
www.valirx.com
Cautionary
statement
Certain statements made in this announcement
are forward-looking statements. Such statements are based on
current expectations and assumptions and are subject to a number of
risks and uncertainties that could cause actual events or results
to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons
receiving this announcement should not place undue reliance on
forward-looking statements. Unless otherwise required by applicable
law, regulation or accounting standard, the Company does not
undertake to update or revise any forward-looking statements,
whether as a result of new information, future developments or
otherwise.